Silence Therapeutics (SLN) EBIT (2019 - 2025)
Historic EBIT for Silence Therapeutics (SLN) over the last 7 years, with Q3 2025 value amounting to -$26.2 million.
- Silence Therapeutics' EBIT rose 1037.6% to -$26.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$83.0 million, marking a year-over-year decrease of 1183.47%. This contributed to the annual value of -$63.3 million for FY2024, which is 284.72% down from last year.
- Silence Therapeutics' EBIT amounted to -$26.2 million in Q3 2025, which was up 1037.6% from -$24.0 million recorded in Q2 2025.
- Silence Therapeutics' 5-year EBIT high stood at -$12880.5 for Q1 2021, and its period low was -$29.3 million during Q3 2024.
- In the last 5 years, Silence Therapeutics' EBIT had a median value of -$16.1 million in 2023 and averaged -$16.4 million.
- As far as peak fluctuations go, Silence Therapeutics' EBIT tumbled by 13704901.42% in 2021, and later surged by 7363.4% in 2024.
- Silence Therapeutics' EBIT (Quarter) stood at -$15.2 million in 2021, then increased by 15.32% to -$12.9 million in 2022, then decreased by 28.39% to -$16.5 million in 2023, then skyrocketed by 73.63% to -$4.4 million in 2024, then plummeted by 503.03% to -$26.2 million in 2025.
- Its last three reported values are -$26.2 million in Q3 2025, -$24.0 million for Q2 2025, and -$28.4 million during Q1 2025.